Pernilla will participate digitally and conduct one-to-one meetings with potential Japanese partners and present the company and the drug candidate Foxy-5. Foxy-5 aims to inhibit the ability of tumour cells to spread in the body and is in phase 2 clinical development. Pernilla will talk about the interesting ad hoc‑observations made in connection with the ongoing study. The study is conducted in patients affected by colon cancer.

Nordic Health Summit Japan is a high-level partner and investor conference that aims to bring together healthcare innovators, investors and industry. The conference is organised by Nordic Innovation House Tokyo, Business Sweden and other Nordic actors.

For further information: 

Pernilla Sandwall, CEO, WntResearch AB 
e-mail: pernilla.sandwall@wntresearch.com 

About Wntresearch AB

WntResearch is developing a completely new type of cancer drug that inhibits the ability of tumour cells to spread in the body and form metastases. The company's research is focused on studying the endogenous protein WNT5A, which in scientific studies has shown to affect tumour cells' ability to move and spread in the body. WntResearch drug candidate Foxy-5 is a peptide that mimics the function of WNT5A and is intended to reduce the mobility and spread of cancer cells thus preventing metastases from occurring. Although current cancer treatment has become more effective, there are no effective ways to prevent the onset of metastases that cause about 90 per cent of all cancer-related deaths. Foxy-5 has a unique mechanism of action and has shown a good safety profile with few side effects in two Phase I clinical trials. The safety and efficacy of Foxy-5 are now being evaluated in the ongoing Phase 2 clinical trial NeoFox, in patients with stage II-III colon cancer.

WntResearch is listed on the Spotlight Stock Market. For more information, please visit: www.wntresearch.com. Follow WntResearch on Linked in